NANJING, China, Jan. 08, 2019 TransThera Biosciences Co. Ltd, announced today the dosing of the first patient in a phase I first-in-human clinical trial of TransThera’s lead product candidate, TT-00420, for the treatment of triple negative breast cancer (TNBC) and advanced solid tumors.
“We are excited to reach a milestone of advancing TT-00420 into clinical stage, and we hope that TT-00420 can transform the treatment landscape for TNBC. We are very grateful to our team, collaborators and clinical PI for fast executing the clinical development plan”, stated Dr. Frank Wu, founder and CEO of TransThera.
The phase I study is a global, multicenter trial involving a dose escalation arm followed by a dose expansion arm to evaluate the safety, tolerability, and efficacy of TT-00420.About TransThera Biosciences
TransThera Biosciences, specialized in developing novel NCE drugs, was founded in 2016 in Nanjing, China. It aims to become an innovation platform company with global vision by adopting a novel business model to adapt internal research and open innovation. TransThera’s current portfolio covers th erapeutic areas such as oncology and inflammatory diseases.About TT-00420
TT-00420 is a selectively clustered multiple kinase inhibitor with novel dual mechanisms affecting cell cycle and tumor microenvironment simultaneously. Its unique profile renders its superior efficacy against certain tumor types such as TNBC in extensive pre-clinical studies. TNBC represents about 15% of all breast cancers. A huge unmet medical need exists, as there is currently no effective target therapy available for treating TNBC.